IL-22RA1, is expressed on epithelial and stromal cells, and its activation by IL-22 promotes cell survival, proliferation, and production of pro-inflammatory mediators. Temtokibart's inhibition of IL-22 signaling aims to reduce pathological tissue remodeling, inflammation, and fibrosis, offering a targeted approach for diseases driven by dysregulated IL-22/IL-22RA1 axis activity.